Sectors
SVRA
Savara Inc.
5.69
4 x 5.69
11 x 5.70
bid
ask
-
0.15
2.49%
01:54 PM
timesize
| Ytd | -5.56% | |
| 1y | 136.29% |
5.65
day range
5.87
2.28
52 week range
7.00
| Open | 5.80 | Prev Close | 5.84 | Low | 5.65 | High | 5.87 | Mkt Cap | 1.20B |
| Vol | 2.19M | Avg Vol | 1.65M | EPS | -0.56 | P/E | -10.43 | Forward P/E | 0.41 |
| Beta | 0.24 | Short Ratio | 15.35 | Inst. Own | 104.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 5.48 | 200-d Avg | 5.33 | 1yr Est | 10.94 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-12 | 2026-06 | -0.14 | N/A | N/A | N/A |
| 2026-05-12 | 2026-03 | -0.14 | -0.15 | -0.01 | -7.14% |
| 2026-03-13 | 2025-12 | -0.12 | -0.13 | -0.01 | -8.33% |
| 2025-11-12 | 2025-09 | -0.13 | -0.14 | -0.01 | -7.69% |
| 2025-08-13 | 2025-06 | -0.12 | -0.14 | -0.02 | -16.67% |
| 2025-05-13 | 2025-03 | -0.12 | -0.12 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-12-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-12-18 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2025-11-14 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2025-11-13 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2025-10-23 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2025-09-09 | Guggenheim | Upgrade | Buy | Buy |
Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-12-08 | ELAM NEVAN C | Director | 106.89K | Stock Award(Grant) |
| 2024-12-11 | ERICKSON ANNE | Officer | 434.67K | Stock Award(Grant) |
| 2025-12-08 | HAWKINS RICHARD JAMES | Director | 161.33K | Stock Award(Grant) |
| 2026-06-21 | LOWRANCE DAVID L. CPA | Chief Financial Officer | 536.03K | Sale |
| 2024-12-11 | LUTZ ROBERT MATTHEW | Chief Operating Officer | 400.00K | Stock Award(Grant) |
| 2026-02-12 | MCCRACKEN JOSEPH S | Director | 302.64K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | NEA Management Company, LLC | 24.47M | 0.00 | 11.94% |
| 2026-03-30 | Bain Capital Life Sciences Investors, LLC | 17.60M | 0.00 | 8.59% |
| 2026-03-30 | VR Adviser, LLC | 13.74M | 0.00 | 6.71% |
| 2026-03-30 | Deerfield Management Co | 13.57M | 0.00 | 6.62% |
| 2026-03-30 | TCG Crossover Management, LLC | 12.36M | 0.00 | 6.03% |
| 2026-03-30 | BlackRock Inc | 11.29M | 0.00 | 5.51% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Polar Capital Healthcare Opports Inc | 8.19M | 0.00 | 4.00% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 6.16M | 0.00 | 3.01% |
| 2026-06-29 | iShares Russell 2000 ETF | 4.03M | 0.00 | 1.97% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 3.18M | 0.00 | 1.55% |
| 2026-03-30 | Pictet-Biotech P USD | 1.64M | 0.00 | 0.80% |
| 2026-06-29 | Vanguard Institutional Extnd Mkt Idx Tr | 1.57M | 0.00 | 0.77% |
Split
| Split | Date |
|---|---|
| 0 : 1 | 2017-04-28 |
| 0.04 : 1 | 2010-04-26 |